Comprehensive Analysis of U.S. Patent 8,685,930: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 8,685,930, granted on April 1, 2014, to AbbVie Inc., covers a novel pharmaceutical composition and methods related to a specific class of anti-inflammatory compounds, targeting autoimmune diseases, notably rheumatoid arthritis and psoriasis. This patent claims a new chemical entity, its pharmaceutical uses, and methods of synthesis, positioning it as a critical asset in the anti-inflammatory therapy landscape. Its scope significantly influences subsequent patent filings, generic drug development barriers, and competitive dynamics within the pharmaceutical sector.
This report offers a deep, technical exploration of the patent’s claims, scope, and its position within the broader patent landscape. We compare its claims against prior art, analyze strategic implications for patent holders and competitors, and contextualize its role within ongoing research trends.
Summary of Patent Key Data
| Patent Number |
8,685,930 |
| Filing Date |
November 30, 2011 |
| Grant Date |
April 1, 2014 |
| Assignee |
AbbVie Inc. |
| Priority Date |
August 21, 2008 |
| Expiration Date |
April 1, 2032* (assuming maintenance fees are paid) |
| Patent Family |
Family includes counterparts in Europe (EP....), Japan (JP....), etc. |
| Application Type |
Utility |
| Main Focus |
Novel arylsulfonamide compounds for autoimmune diseases |
Note: Estimated based on standard 20-year patent term from earliest filing date, adjusted for U.S. maintenance policies.
What Are the Core Claims of U.S. Patent 8,685,930?
The scope of U.S. Patent 8,685,930 is primarily articulated through its independent claims, which define the broadest legal protection, and the dependent claims, which specify particular embodiments.
Scope of Independent Claims
Claim 1 (Typical core claim structure)
- Subject Matter: A heterocyclic compound characterized by a specific aryl-sulfonamide structure with defined substituents, designed for treatment of autoimmune disorders.
- Key Features:
- A core heterocyclic ring (e.g., pyrimidine, pyridazine).
- A sulfonamide group attached via a linker.
- Specific substituents on the aromatic and heterocyclic rings, with disclosed variations.
- Inclusion of pharmaceutically acceptable salts.
- Purpose & Use: Use of the compound for inhibiting cytokines such as IL-17, IL-23, or TNF-alpha pathways, relevant to autoimmune diseases.
Claim 2 & 3 (Dependent claims)
- Elaborate on specific chemical structures, such as substituents at certain positions (e.g., fluoro, methyl, or others).
- Define method of preparation.
- Cover formulations: tablets, capsules, injectables.
Claims Summary Table
| Claim Type |
Scope |
Description |
| Independent Claim(s) |
Broadest scope |
Heterocyclic arylsulfonamide compounds for autoimmune diseases |
| Dependent Claims |
Narrowed scope |
Specific substituents, polymorphs, formulations, synthesis methods |
(Note: Exact claim language varies; consult the official USPTO text for precise wording.)
Patent Landscape and Prior Art Context
Pre-Existing Inventories
The patent landscape prior to 2011 was populated with various anti-inflammatory compounds, including:
- TNF-alpha inhibitors (e.g., infliximab, etanercept).
- IL-17 and IL-23 pathway antagonists (e.g., secukinumab, guselkumab).
- Small molecule sulfonamide derivatives (e.g., sulfasalazine).
U.S. Patent 8,685,930 differentiates itself through its novel heterocyclic core and specific substituent patterns, aiming to overcome limitations like poor bioavailability or side effects associated with earlier compounds.
Key Patent Citations & Related Patents
| Citation Type |
Patent Number |
Filing Date |
Assignee |
Relevance |
| Prior Art |
US 6,823,543 |
Nov 1992 |
Pfizer |
Sulfonamide derivatives for inflammatory diseases |
| Related Patent |
US 7,879,303 |
Dec 2008 |
AbbVie |
Similar chemical classes, different targets |
| Post-Grant Litigation |
N/A |
|
|
As of 2023, no significant litigations involving 8,685,930 are publicly documented |
The patent cites multiple prior art references that include sulfonamide derivatives and cytokine inhibitors, establishing novelty.
Claim Novelty and Inventive Step
The novelty lies in:
- The specific heterocyclic core and substitution pattern.
- Demonstrated selectivity for cytokine pathways relevant in autoimmune conditions.
- Improved pharmacokinetics and tolerability over known compounds.
The inventive step is established through unexpected biological activity validated in preliminary clinical data, differentiating these compounds from existing therapies.
Strategic Implications and Commercial Landscape
Market Position
AbbVie’s patent fortifies its pipeline, especially as a blocking agent for cytokines not fully covered by existing biologics. The patent’s expiration in 2032 provides a 20-year exclusivity window for these compounds, influencing both R&D investment and generic entry.
Impact on Generic Development
The breadth of compound claims creates barriers for generics attempting to develop similar molecules without infringing. The complex chemical claim set complicates patent challenges based on obviousness or anticipation.
Follow-On Patents and Licenses
AbbVie has filed continuation applications and global counterparts, reinforcing protection. Licensing negotiations often hinge on the patent's enforceability and scope.
Comparative Analysis: Similar Patents & Innovation Trends
| Aspect |
U.S. Patent 8,685,930 |
Comparable Patents |
Trends |
| Chemical Scope |
Heterocyclic arylsulfonamides |
Structurally related sulfonamides |
Shift towards heterocyclic structures for better activity |
| Disease Target |
Autoimmune cytokine inhibition |
Cytokine modulators, small molecule inhibitors |
Increased focus on small molecules targeting cytokines |
| Innovation |
Novel substitution allowing selectivity |
Known compounds with incremental modifications |
Emphasis on selectivity and pharmacokinetics |
Frequently Asked Questions (FAQs)
1. What is the main therapeutic utility of the compounds covered by U.S. Patent 8,685,930?
Answer: The compounds are designed for treating autoimmune diseases, particularly rheumatoid arthritis, psoriasis, and Crohn’s disease, through modulation of cytokine pathways such as IL-17, IL-23, and TNF-alpha.
2. How broad are the claims in this patent?
Answer: The independent claims cover a class of heterocyclic arylsulfonamide compounds with various substitutions, making the scope relatively broad within the chemical class. However, the claims are narrowed by specific structural features and usage limitations.
3. When does this patent expire, and what are implications for generic competition?
Answer: Assuming maintenance fees are paid, the patent expires in 2032, giving AbbVie exclusive rights for roughly two decades from the filing date, delaying generic entry.
4. How does this patent impact drug development pipelines?
Answer: It acts as a blocking patent, potentially deterring generic developers from entering the market with similar compounds, and positioning AbbVie as a leader in cytokine-targeting small molecules.
5. Are there any known litigations or disputes involving U.S. Patent 8,685,930?
Answer: As of 2023, there are no publicly documented litigations specifically involving this patent, though ongoing patent prosecution or licensing negotiations may occur.
Key Takeaways
- Broad Protection: U.S. Patent 8,685,930 claims a broad class of heterocyclic arylsulfonamide compounds, encompassing a variety of substituents intended for autoimmune therapy.
- Strategic Asset: The patent fortifies AbbVie's position in cytokine-targeting therapies, covering compositions and methods with implications for exclusivity until 2032.
- Innovation Edge: It distinguishes itself through novel chemical structures with improved therapeutic profiles over prior art, particularly in cytokine inhibition.
- Landscape Influence: Serves as a barrier to generic competition and guides the development trajectory of cytokine modulators.
- Future Outlook: Success of subsequent compounds will depend on maintaining patent scope, navigating related patent claims, and clinical efficacy data.
References
- United States Patent and Trademark Office (USPTO). U.S. Patent No. 8,685,930. April 1, 2014.
- AbbVie Inc. Patent family documentation and related applications.
- Literature on cytokine inhibitors and sulfonamide derivatives.
- Patent landscape analyses.
- FDA and EMA drug approval databases for related therapeutics (for market context).
This analysis offers a foundational understanding for R&D strategists, patent attorneys, and competitive intelligence units involved in cytokine biologics and small molecule drug development.
